Data from New Analyses of Studies with Veltassa® Presented at 53rd European Renal Association Congress
May 22, 2016 11:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 22, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa® (patiromer) for...
Relypsa Announces New Employment Inducement Grants
May 18, 2016 16:05 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 16, 2016, the compensation committee of the company’s...
Relypsa Announces New Employment Inducement Grants
May 05, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 2, 2016, the compensation committee of the company’s...
Relypsa Reports First Quarter 2016 Financial Results
May 04, 2016 16:05 ET
|
Relypsa, Inc.
Relypsa Management to Host Conference Call/Webcast this Afternoon at 5:00 p.m. ET/2:00 p.m. PT REDWOOD CITY, Calif., May 04, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a...
Relypsa Announces $150 Million Debt Financing
May 03, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced the closing of $150 million in aggregate principal amount of senior...
Relypsa to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
May 02, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., May 02, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Bank of America...
Data from New Analyses of Studies with Veltassa® Presented at National Kidney Foundation 2016 Spring Clinical Meetings
April 28, 2016 18:00 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced data from new analyses of studies with Veltassa® (patiromer) for...
Relypsa to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
April 27, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results...
Vifor Fresenius Medical Care Renal Pharma and Relypsa Announce Submission of Marketing Authorization Application Requesting European Approval of Veltassa® for the Treatment of Hyperkalemia
April 25, 2016 08:30 ET
|
Relypsa, Inc.
ST. GALLEN, Switzerland and REDWOOD CITY, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical...
Relypsa Announces Upcoming Veltassa® Data Presentations at National Kidney Foundation 2016 Spring Clinical Meetings
April 21, 2016 16:15 ET
|
Relypsa, Inc.
REDWOOD CITY, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that new analyses from studies of Veltassa® (patiromer) for oral...